Obesity, one of the most pressing health issues of our time, is driven by complex factors that range from genetics to environment and lifestyle. But now, researchers at the Université de Montréal’s affiliated hospital research center (CRCHUM) may have uncovered a promising new approach to tackling obesity by targeting brain molecules that control food cravings.
Targeting the Brain to Control Weight Gain
In a groundbreaking study published in Nature Communications, Dr. Stephanie Fulton and her team at CRCHUM explored how the brain regulates food intake and energy expenditure, offering new hope for combating obesity. Specifically, they focused on the enzyme ABHD6, which degrades an important endocannabinoid molecule called 2-arachidonoylglycerol (2-AG) in the brain.
Endocannabinoids, which are naturally occurring compounds in the brain, play a significant role in regulating appetite and food reward. By targeting ABHD6, Fulton and her team discovered a novel way to reduce weight gain in mice without inducing anxiety or depression—a problem associated with some past weight-loss drugs.
The Role of ABHD6 in the Brain
Fulton’s research builds on earlier work showing that inhibiting ABHD6 in the body reduces obesity and prevents diabetes. However, the team sought to understand its role specifically within the brain and its impact on appetite and body weight. They focused on the nucleus accumbens, a brain region rich in endocannabinoids that controls food reward and physical activity.
By deleting the gene for ABHD6 in this part of the brain, the researchers observed a surprising effect. Mice with this genetic modification showed less interest in food and more enthusiasm for physical activity. These mice spent significantly more time on a running wheel compared to the control group, which became obese and lethargic on a high-fat diet.
Moreover, when ABHD6 inhibitors were directly injected into the brains of the mice, they were fully protected from weight gain, despite consuming a high-fat diet.
The Importance of Targeting Specific Brain Regions
What sets this study apart is its focus on targeting specific neuronal pathways in the brain, which could allow for more precise treatments for obesity and related metabolic disorders. In earlier work, the same research group showed that blocking ABHD6 in certain hypothalamic neurons made mice resistant to weight loss. In contrast, inhibiting ABHD6 in the nucleus accumbens resulted in significant reductions in weight gain.
This finding underscores the complexity of brain signaling and suggests that inhibiting ABHD6 can have opposing effects depending on the brain region targeted. In the nucleus accumbens, the inhibition of ABHD6 led to greater physical activity and less food intake, providing a potential therapeutic avenue for managing obesity.
No Signs of Anxiety or Depression
One of the major concerns with cannabinoid-targeting drugs is the potential for psychiatric side effects. For instance, Rimonabant, a weight-loss drug that targeted cannabinoid receptors, was withdrawn from the market in the 2000s due to serious side effects, including depression and suicidal tendencies.
However, Fulton’s team found no such adverse effects in their mice models. The mice with inhibited ABHD6 did not display signs of anxiety or depression, making this discovery especially promising. It suggests that ABHD6 inhibitors could potentially offer an obesity treatment without the dangerous side effects seen with previous cannabinoid-based drugs.
The Road Ahead: From Mice to Humans
While these results are promising, much remains to be done before this approach can be tested in humans. The next step involves further research to confirm whether these brain mechanisms are the same in humans and to screen for potential ABHD6 inhibitors that could be developed into drugs.
However, the implications of this study are clear: scientists are beginning to unlock new ways to control food cravings and weight gain at the neurological level, potentially offering a safer and more effective treatment for obesity and metabolic disorders like type 2 diabetes.
As the research progresses, the team hopes to pave the way for novel therapies that could one day help millions of people struggling with obesity, providing a more targeted and effective solution than what is currently available.
Related Topics:
Is Orlistat Compatible With Other Weight Loss Methods?
